Estrogen (E2) signaling through the activity of the E2 receptor *α* (ER*α*) is essential in the rodent uterus for the establishment of pregnancy. ER*α* can be detected in the three main cell types within the uterus: epithelial cells, myometrial cells, and stromal cells. Epithelial cells line the lumen and the glands emanating from the lumen, the myometrial layers wrap around the exterior of the uterine tube, and the stromal cells are between the epithelial and myometrial layers. In sexually mature ovariectomized animals, E2 initiates proliferation specifically of the epithelial cell layer, leading ultimately to a transition of the single layer of cuboidal cell epithelium into a hypertrophied hyperplastic secretory layer. Studies by Cooke and colleagues ([@B1]), using recombination of isolated immature uterine cells, indicated the importance of the ER*α* in stromal cells in this response and described a mechanism in which stromal cell ER*α* induces mitogenic signals, later shown to be growth factors, which act in a paracrine manner to activate epithelial cell growth factor receptor signaling ([@B2]). Studies using adult *Wnt7a*^Cre^ mice to selectively delete ER*α* in uterine epithelial cells (*Wnt7a*^Cre+^;*Esr1*^f/f^, called ER*α*EpicKO) further confirmed this mechanism in an adult *in situ* tissue, as E2 could still induce uterine epithelial cell growth ([@B3]).

Several candidate mitogenic factors have been studied as mediators of the paracrine growth response. Insulinlike growth factor 1 (IGF1) is one candidate, considering E2 induces its transcript as well as the protein, primarily in stromal cells ([@B2][@B4]). In addition, epithelial cells have IGF1 receptors (IGF1Rs), and evidence for activation of uterine IGF1R signaling is observed following E2 treatment ([@B5]). IGF1-null mice lack a full uterine epithelial growth response to E2 ([@B6]) and directly administering IGF1 to mice induces uterine epithelial cell growth ([@B7]). The absence of uterine epithelial growth response in global ER*α*-null mice (called *α*-ERKO or Ex3*α*ERKO) following IGF1 treatment indicates a direct role for ER*α* in mediating the IGF1 signal ([@B7][@B8]). These findings led us to a model in which IGF1R signals "cross-talk" to the ER*α*, resulting in E2-like ER*α*-mediated responses. The global ER*α*-null models have additional phenotypes, such as obesity and insulin resistance, related to loss of E2 signaling in all tissues, that might impact uterine responsiveness. To more specifically address the role of uterine ER*α* in mediating the IGF1 response, we assessed the IGF1 transcriptional responses in *Pgr*^Cre+^;*Esr1*^f/f^ (called ER*α*UtcKO) mice, which selectively lose ER*α* from progesterone receptor (PGR) expressing cells, including all uterine cells, while maintaining ER*α* expression in other tissues and cells. Herein, we explore the transcriptional and molecular signaling within wild-type (WT) and ER*α*-null contexts that underlies our findings to refine our understanding of IGF1 signaling in uterine transcriptional responses.

Materials and Methods {#s1}
=====================

Mice {#s2}
----

All mice were handled in accordance with protocols approved by the National Institute of Environmental Health Sciences (NIEHS) Animal Care and Use Committee in compliance with the National Research Council's *Guide for the Use and Care of Laboratory Animals* ([@B9]). In this study, Ex3*α*ERKO mice used as a global ER*α*-null model and WT control littermates were bred from our contract colony (Taconic Biosciences, Albany, NY) and uterine ER*α*-null mice (*Pgr*^Cre+^;*Esr1*^f/f^ or ER*α*UtcKO) were bred from an NIEHS colony. Both colonies were genotyped by Transnetyx Inc. (Cordova, TN). Eight weeks or older female Ex3*α*ERKO or ER*α*UtcKO mice and their WT littermates were ovariectomized and rested for 10 to 14 days to clear endogenous ovarian hormones. Animals were randomly divided into treatment groups: estradiol (*i.e.*, E2; Research Plus Inc., Barnegat, NJ; 250 ng/100 μL saline) or normal saline vehicle (V) was administered by intraperitoneal injection, and uterine tissue was collected 2 or 24 hours later. IGF1 (Recombinant Human LR3 IGF1; Cell Sciences, Newburyport, MA) was either given by intraperitoneal injection (50 μg in 100 μL phosphate-buffered saline) and uterine tissue was collected after 1 or 2 hours, or for longer treatment, IGF1 was administered using an Alzet model 1003D osmotic pump (Durect Corporation, Cupertino, CA) filled with 100 μL 0.5 mg IGF1/mL 0.1 N acetic acid and uterine tissue was collected 24 hours later. The ER*α* antagonist ICI 182,780 was administered by intraperitoneal injection (Tocris Biosciences, Bristol, UK, 45 μg/50 μL DMSO) 30 minutes prior to V, E2, or IGF1 injection to a subgroup of WT mice. In the case of V and 24-hour samples, a piece of the uterine sample was fixed in 10% formalin (Thermo Fisher Scientific, Rockford, IL) for further analysis. The remaining uterine tissue as well as 2-hour samples were snap frozen in liquid nitrogen, and processed for RNA extraction using Trizol reagent (Thermo Fisher Scientific) as previously described ([@B10]). RNA was used for real-time (RT) polymerase chain reaction (PCR) or microarray. Additional ovariectomized WT mice were collected 1 hour after intraperitoneal injection of V, E2, IGF1, or ICI; snap frozen; and sent to Active Motif (Carlsbad, CA) for ER*α* chromatin immunoprecipitation (ChIP) sequencing (seq) or ChIP-PCR analyses.

Immunohistochemistry {#s3}
--------------------

Uterine tissue was embedded in paraffin, cut into 4-μM sections onto charged slides. Sections were deparrafinized, decloaked in a Biocare Decloaking Chamber with Biocare 1× Antigen Decloaking Buffer (Biocare Medical, Pacheco, CA) and blocked with 5% H~2~O~2~. Sections were blocked with 10% Normal Horse Serum (Jackson Immunoresearch, West Grove, PA) then incubated with mouse antihuman Ki-67 \[BD Pharmingen/BD Biosciences, San Jose, CA; Catalog No. 550609; research resource identifier (RRID): AB_393778\] diluted 1:100 or anti-ER*α* (Biocare Medical ER- 1D5 Catalog No. ACA 054C, RRID: AB_2651037) 1:200 in 10% Normal Horse Serum and developed with biotinyl-anti-mouse immunoglobulin G (Vector Laboratories, Burlingame, CA), and Extravidin Peroxidase (Sigma Chemical St Louis MO) and Dako Products DAB (Agilent Technologies, Santa Clara, CA).

RT-PCR {#s4}
------

Complementary DNA was synthesized from 1 to 2 µg of uterine RNA as previously described ([@B10]), diluted 1:100 in water, and analyzed by RT-PCR using Fast Sybr Master Mix (Thermo Fisher Scientific, Grand Isle, NY) and primers to transcripts of interest (synthesized by Sigma Genosys, The Woodlands, TX; sequences in Supplemental Table 2) as previously described ([@B10]).

Microarray and data analysis {#s5}
----------------------------

Isolated RNA was further cleaned up using the Qiagen RNeasy Kit clean-up protocol with DNase treatment (Qiagen, Germantown, MD) and submitted to the NIEHS Microarray Group/Molecular Genetics Core for analysis using the Affymetrix Mouse Whole Transcriptome Array (Affymetrix, Santa Clara, CA). Data were analyzed using Partek Genomics Suite 6.6 (Partek Inc., St. Louis, MO) and Ingenuity Pathway Analysis (Qiagen). Microarray data are deposited in the Gene Expression Omnibus (GEO) database accession number GSE100131.

ChIP-seq and ChIP-PCR {#s6}
---------------------

Uterine tissue was shipped to Active Motif Inc. for ER*α* ChIP-seq or ChIP-PCR. ChIP-seq libraries were sequenced either single-end 36-mers or single-end 50-mers; for consistency, all reads were trimmed to 36-nt as the first step of data processing. The raw sequence reads were then filtered to remove any entries with a mean base quality score \<20. Reads were mapped against the mm10 reference genome via Bowtie (v0.12.8) ([@B11]), with only uniquely mapped hits accepted. Duplicate mapped hits were removed with Picard tools MarkDuplicates.jar (v1.110). Peak calls were made by HOMER (v4.7.2) ([@B12]) with parameters "-fdr 0.00001 -F 12 -style factor." For consistency across datasets, each HOMER peak was redefined as a 200-nt region centered on the midpoint of the called peak. An overlap analysis was performed between peak sets, where two peaks must share a minimum of 100-nt to be considered overlapping. Peaks were assigned to gene loci according to the closest transcription start site (TSS) with maximum distance of 50 kb, considering only genes that are expressed in mouse uterus. Genes qualified as "expressed" if they had an average fragments per kilobase of exon per million fragments mapped of at least 0.5 in V-treated or E2-treated RNA-seq samples (unpublished data). The gene models used for this analysis are based on RefSeq as downloaded from the University of California, Santa Cruz Genome Browser on 9 February 2015. Data are deposited in the GEO database accession number GSE100023.

Statistical analysis {#s7}
--------------------

Values were compared using statistical tools in Graphpad Prism 7. Two-way analysis of variance with multiple comparisons using Fisher's least significant difference.

Results {#s8}
=======

Previously, we reported that global ER*α*-null (*α*-ERKO and Ex3*α*ERKO) females lacked uterine growth following IGF1 treatment ([@B7][@B8]). Analysis indicated that IGF1R was present in ER*α*-null uterine tissue ([@B7]). IGF1R-mediated signaling was intact as shown by increased phosphorylation of uterine IGF1R, AKT, and mitogen-activated protein kinase, and association of IRS1 and P85 with the IGF1R following IGF1 treatment of ER*α*-null mice ([@B7]). To directly test the effect of ER*α* signaling on uterine IGF1 response, the ER*α* antagonist ICI 182,780 (ICI; fulvestrant) was administered to WT mice 30 minutes prior to E2 or IGF1 treatments. ICI effectively inhibited E2 response, but did not impair IGF1 induction of uterine epithelial cell growth as reflected by increase in the Ki67 protein \[[Fig. 1(a](#F1){ref-type="fig"})\]. We previously reported that some E2 responsive uterine transcripts can also be regulated by IGF1 ([@B13]). Evaluation of four uterine transcripts that we have previously characterized as E2 or IGF1 regulated ([@B13]) by RT-PCR indicates that the E2 induction of cyclin-dependent kinase 1a (*Cdkn1a*) and nuclear receptor 4a1 (*Nr4a1*) was inhibited by ICI, and the E2 repression of thioredoxin-interacting protein (*Txnip*) and *Sry-Box4* (*Sox4*) was partly inhibited by ICI. However, the IGF1 responses tested in WT mice were not inhibited by ICI \[[Fig. 1(b](#F1){ref-type="fig"})\]. The inability of ICI to inhibit uterine growth or gene regulation suggests that ER*α* is not required for IGF1-mediated responses in the WT context, where ER*α* is present.

![ER*α* antagonist does not inhibit IGF1-induced uterine growth or gene regulation. (a) Ki67 proliferative marker immunohistochemistry of uterine samples from WT mice treated for 24 hours with saline V, E2, or IGF1 either alone (--ICI) or in combination with the ER*α* antagonist ICI 182,780 (+ICI). Scale bars = 60 µM. (b) RT-PCR shows that transcripts that are induced (*Cdkn1a*, *Nr4a1*) or repressed (*Txnip*, *Sox4,*) by E2 (2 hours) are also regulated by IGF1 (2 hours). ICI inhibits the E2-mediated upregulation, and partially inhibits the E2-mediated downregulation, but does not affect the IGF1-mediated regulation. Black bars: no ICI; gray bars: with ICI. Two-way analysis of variance with posttest \**P* \< 0.05, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001 vs V; +*P* \< 0.05, ++*P* \< 0.01 no ICI vs with ICI; \#\#\#\# *P* \< 0.0001 E2 vs IGF1. N = 4 or 5 for all samples.](en.2017-00349f1){#F1}

To address this discrepancy in the necessity for ER*α* in uterine responses to IGF1, we assessed mechanisms mediating IGF1-induced transcriptional responses in ER*α*-null vs ER*α*-containing contexts. We evaluated transcriptional profiles of uterine tissue from ovariectomized WT and Ex3*α*ERKO mice following E2 or IGF1 treatments. In addition, we evaluated uterine RNA samples from mice with uterine selective ER*α* deletion (ER*α*UtcKO), following E2 or IGF1 treatments. The ER*α*UtcKO mouse was made by crossing *Esr1*^f/f^ mice with *Pgr*^Cre+^ mice. These mice have deletion of ER*α* in all PGR expressing cells, including all uterine cells (Supplemental Fig. 1). Treatment groups as well as the number of samples in each treatment group evaluated by microarray are summarized in Supplemental Table 1. Principle component analysis of the sample means revealed three groupings of samples \[[Fig. 2(a](#F2){ref-type="fig"})\] that reflect several conclusions. First, that both ER*α*-null models treated with E2 (KO E2) clustered together with all the V-treated samples, indicating lack of transcriptional response to E2 in the ER*α*UtcKO and Ex3*α*ERKO, as expected. That is, the ER*α*-null models, when treated with E2, do not yield a transcriptional response, hence the sample means cluster together with V-treated samples from all genotypes. The second group included WT samples treated for 2 hours with E2 or IGF1, indicating that IGF1 and E2 elicit similar transcriptional responses. Additionally, ER*α*UtcKO and Ex3*α*ERKO samples treated with IGF1 for 2 hours were in this group, showing that the IGF1 response is similar and indicating ER*α* independence of the overall transcriptional response. Similarly, the third group contained WT samples treated for 24 hours with E2 or IGF1 together with ER*α*UtcKO and Ex3*α*ERKO samples treated with IGF1 for 24 hours. The same grouping is evident in a hierarchically clustered heatmap of the 12,000 differentially expressed (DE; less than twofold, false discovery rate \< 0.05) transcripts (Supplemental Fig. 2). Like our previous findings ([@B13]), the patterns of gene expression following E2 or IGF1 are similar to each other in WT, and the IGF1 response also occurs in Ex3*α*ERKO. In addition, we now observe IGF1 responses in ER*α*UtcKO samples. Consistent with our previous report ([@B13]), WT responses to E2 include some transcripts that are not impacted by IGF1 \[Supplemental Fig. 2; [Fig. 2(b)](#F2){ref-type="fig"}, yellow boxes\]. E2 treatment increases IGF1 synthesis and IGF1R-mediated signaling in uterine tissue, with a peak of *Igf1* transcript occurring 4 to 6 hours after E2 is administered ([@B14]), and subsequent IGF1R activation observed 6 to 24 hours after E2 treatment ([@B15]). Because of this, the responses observed 24 hours following E2 will be affected by induction of IGF1 signals. Therefore, we focused on the transcriptional responses 2 hours after E2 or IGF1 treatments to find responses without the influence of secondary IGF1R-mediated signals; 7500 transcripts were differentially expressed in response to 2 hours IGF1 or E2 \[[Fig. 2(b](#F2){ref-type="fig"})\].

![Microarray analysis of E2- and IGF1-regulated transcripts. (a) Principal component analysis of all sample means from WT (diamond), ER*α*UtcKO (triangle), and Ex3*α*ERKO (square) uterine RNA from V, E2, or IGF1 treatments for 2 hours or 24 hours. Red = E2 (24 hours), blue = E2 (2 hours), green = IGF1 (24 hours), purple = IGF1 (2 hours), orange = V. Numbers of each sample are detailed in Supplemental Table 1. (b) Hierarchical cluster of DE (intensity \>100, twofold, false discovery rate \<0.05) probes. Green box, probes DE by IGF1; yellow box, probes DE only by E2.](en.2017-00349f2){#F2}

Probes (654 total, 262 for coding RNA) that might reflect IGF1 response independent of ER*α* were selected from a comparison of genes DE after IGF1 treatment of WT and ER*α*UtcKO mice while excluding those DE after IGF1 treatment of Ex3*α*ERKO mice \[[Fig. 3(a](#F3){ref-type="fig"})\]. Although Ex3*α*ERKO IGF1 responses are also ER*α*-independent and are similar to WT and ER*α*UtcKO responses, we focused on WT and ER*α*UtcKO responses to minimize effects that global ER*α* deletion might have on the uterine tissue responsiveness. Enriched biological functions associated with these 654 DE genes \[Supplemental Fig. 3(a)\] include activation of transcription and cell survival, and suppression of cell death. Additionally, the regulation pattern of the 654 transcripts is consistent with activation of various receptor-mediated tyrosine kinase signals, including transforming growth factor-*β*1 and phosphoinositide 3-kinase. Three transcripts \[FBJ osteosarcoma oncogene (*Fos*), peroxisome proliferator-activated receptor gamma coactivator 1-*α* (*Ppargc1α*), and a disintegrin-like and metallopeptidase with thrombospondin type 1 motif, 5 (*Adamts5*)\] selected from the 654 ER*α*-independent probes were verified using RT-PCR. All three transcripts were regulated by E2 in WT samples, and *Adamts5* and *Ppargc1α* were regulated by IGF1 treatment of both WT and ER*α*-null mice \[[Fig. 3(b](#F3){ref-type="fig"})\]. *Fos* was increased by IGF1 treatment in WT and ER*α*-null samples; however, the induction did not reach significance. RT-PCR findings indicate that *Adamts5* and *Ppargc1α* are regulated by IGF1 in Ex3*α*ERKO, despite exclusion of Ex3*α*ERKO IGF1 responses when the ER*α*-independent transcripts were selected using the analysis in [Fig. 3(a)](#F3){ref-type="fig"}. This pattern is, however, consistent with ER*α*-independent regulation of these uterine transcripts by IGF1. ICI did not inhibit regulation of these transcripts by IGF1 in WT mice \[[Fig. 3(c](#F3){ref-type="fig"})\], also indicative of ER*α* independence.

![ER*α*-independent transcriptional responses. (a) Left: Venn diagram showing selection of 654 ER*α*-independent probes from overlap of transcripts DE by IGF1 in WT and ER*α*UtcKO, but not Ex3*α*ERKO. Right: Hierarchical cluster of the 654 transcripts. (b) RT-PCR showing IGF1 (2 hours) regulation of *Fos*, *Ppargc1a*, and *Adamts5* is ER*α* independent. Black = V, gray = E2, white = IGF1. Two-way analysis of variance with posttest. \**P* \< 0.05, \*\**P* \<0.01, \*\*\**P* \<0.001, \*\*\*\**P* \<0.0001 vs V; +*P* \< 0.05, ++*P* \< 0.01, +++*P* \< 0.001, ++++*P* \<0.0001 vs WT; \#*P* \< 0.05, \#\#*P* \< 0.01, \#\#\#*P* \< 0.001, \#\#\#\#*P* \< 0.0001 E2 vs IGF1. N = 3 to 7 for all samples. (c) ICI does not inhibit IGF1 (2 hours) regulation of *Fos*, *Ppargc1a*, and *Adamts5* consistent with an ER*α*-independent mechanism. Black = no ICI, gray = with ICI. Two-way analysis of variance with posttest \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs V; +*P* \< 0.05, ++++*P* \< 0.0001 no ICI vs with ICI; \#\#*P* \< 0.01 E2 vs IGF1. N = 4 to 5 for all samples.](en.2017-00349f3){#F3}

In the ER*α*-null context, IGF1 is unable to induce a uterine growth response to IGF1 ([@B8][@B13]), despite the transcriptional responses that occur. We therefore evaluated our microarray data for possible ER*α*-dependent WT responses to better understand IGF1-induced transcriptional responses that might underlie the ER*α*-dependent WT growth response. Transcripts that might reflect IGF1 responses mediated by ER*α* were selected using Venn diagrams to choose 230 DE ER*α*-dependent array probes (98 probes for noncoding RNA, 132 probes for coding RNA). The goal was to focus on transcripts that are regulated by E2 or IGF1 in WT, but not regulated by IGF1 in ER*α*UtcKO uteri \[[Fig. 4(a](#F4){ref-type="fig"})\]. Enriched biological functions associated with these DE genes were identified using Ingenuity Pathway Analysis \[Supplemental Fig. 3(b)\]. Activation of cell proliferation, suppression of cell death and activation of steroid synthesis were associated with these genes. Additionally, the regulation pattern of the 230 probes is consistent with activation of E2 and transforming growth factor-*β*1 signaling and with suppression of hepatocyte nuclear factor-1 homeobox A and leukemia inhibitory factor responses.

![Selecting ER*α*-dependent transcriptional responses. (a) Left: Venn diagram showing selection of 230 ER*α*-dependent probes from overlap of transcripts DE by E2 and IGF1 in WT, but not by IGF1 in ER*α*UtcKO. Right: Hierarchical cluster of the 230 transcripts. (b) Venn diagram and table comparing E2- and IGF1-induced ER*α* binding sites and their enriched DNA motifs. (c) Venn diagram comparing the 1826 TSS closest to overlapping E2 and IGF1 ER*α* ChIP-peaks and the 132 coding RNA transcripts from the 230 transcripts selected in (a). The symbols of the 25 overlapping genes are listed. RT-PCR tested shaded genes.](en.2017-00349f4){#F4}

To address whether ER*α* recruitment to chromatin was involved in ER*α*-dependent IGF1 transcriptional responses, we compared ER*α* ChIP-seq of uterine tissue from ovariectomized mice that were treated for 1 hour with V, E2, or IGF. Like E2, IGF1 increased ER*α* binding to uterine chromatin, although administering IGF1 resulted in fewer ER*α* binding peaks than administering E2 ([Table 1](#T1___1){ref-type="table"}). To assess whether E2 and IGF1 treatments recruited ER*α* to similar or different chromatin sites, we compared enriched DNA motifs in all overlapping and nonoverlapping E2 or IGF1 ER*α* peaks \[[Fig. 4(b](#F4){ref-type="fig"})\]. Of the 10,047 IGF1 ER*α* binding peaks, 4821 overlapped with the E2 ER*α* binding peaks. We found that 45% of all E2 peaks and 29% of all IGF1 peaks had enrichment of an estrogen response element (ERE) motif. The ERE motif was enriched in 59% of the E2 peaks overlapping with IGF1 peaks, indicating that both IGF1 and E2 facilitate ER*α* binding to its preferred ERE motif, potentially driving the ER*α*-dependent responses. The Homeobox a9 (Hoxa9) and early growth response 1 (Egr1) motifs were noticeably more enriched in the IGF1 peaks that did not overlap with E2 peaks.

###### 

**ER*α* ChIP-seq**

  **Sample**     **ER*α* Peaks**
  -------------- -----------------
  V              1548
  E2, 1 hour     22,412
  IGF1, 1 hour   10,047
  ICI, 1 hour    24,994

Our analysis suggested that 230 E2- or IGF1-regulated probes are potentially mediated by a mechanism utilizing ER*α* directly \[[Fig. 4(a](#F4){ref-type="fig"})\], and our ER*α* ChIP-seq analysis suggested that IGF1 increases ER*α* chromatin binding ([Table 1](#T1___1){ref-type="table"}). Therefore, we compared expressed genes located nearest the ER*α* binding sites seen in both E2- and IGF1-treated ER*α* ChIP-seq samples to the 132 coding ER*α*-dependent E2- and IGF1-regulated transcripts from the microarray. We limited our analysis of microarray data to probes with coding annotations to facilitate comparison with annotated Refseq transcripts nearest ER*α* binding sites. Twenty-five genes with both E2 or IGF1 ER*α* binding within 50 kb and IGF1-induced transcriptional regulation were identified \[[Fig. 4(c](#F4){ref-type="fig"})\]. Four of these ER*α*-dependent transcripts \[24-dehydrocholesterol reductase (*Dhcr24*), wingless-type MMTV integration site family, member 4 (*Wnt4*), nerve growth factor receptor (*Ngfr*), and mitogen-activated protein kinase kinase 6 (*Map2k6*)\] were verified using RT-PCR. All four transcripts were regulated by both E2 and IGF1 in WT samples \[[Fig. 5(a](#F5){ref-type="fig"})\]; *Ngfr* and *Map2k6* were not regulated by either E2 or IGF1 in ER*α*-null samples, indicating their ER*α* dependence. IGF1 induction of *Dhcr24* and *Wnt4* was observed in the Ex3*α*ERKO. Examination of the ChIP-seq profiles near these transcripts indicated E2 and IGF1 both increased ER*α* recruitment \[Supplemental Fig. 4(a), boxed areas\] consistent with an ER*α*-dependent mechanism for an IGF1-induced response. In WT mice, the ER*α* antagonist ICI was effective in blocking induction of *Dhcr24*, *Ngfr*, and *Wnt4* in response to either E2 or IGF1, also consistent with an ER*α*-dependent mechanism \[[Fig. 5(b](#F5){ref-type="fig"})\]. ICI inhibited E2 repression, but not IGF1 regulation of *Map2k6* in WT. ChIP-seq data indicated that IGF1 increased ER*α* binding near these transcripts. We used ER*α* ChIP-PCR to verify ER*α* binding near *Dhcr24*, *Ngfr* and *Wnt4*. In fact, V uterine samples exhibited ER*α* binding to sites near the three induced transcripts that was increased by E2 or IGF1 treatment \[[Fig. 5(c](#F5){ref-type="fig"})\], consistent with a direct role for ER*α* in mediating some of the uterine transcriptional response to IGF1.

![Verification of ER*α*-dependent transcriptional responses. (a) RT-PCR showing E2 (2 hours) and IGF1 (2 hours) induction of *Dhcr24*, *Wnt4*, and *Ngfr* and repression of *Map2k6* is ER*α* dependent. Two-way analysis of variance with posttest \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs V; ++*P* \< 0.01, +++*P* \< 0.001, ++++*P* \<0.0001 vs WT; \#\#\#*P* \< 0.001, \#\#\#\#*P* \< 0.0001 E2 vs IGF1. N = 3 to 7 for all samples. Black = V, gray = E2, white = IGF1. (b) ICI inhibits E2 (2 hours) and IGF1 (2 hours) induction of *Dhcr24*, *Wnt4* and *Ngfr*, consistent with a two-way analysis of variance with posttest \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001 vs V; +*P* \< 0.05, +++*P* \< 0.001 vs --ICI; \#*P* \< 0.05 E2 vs IGF1. N = 4 to 5 for all samples. Black = no ICI, gray = with ICI. (c) ChIP-PCR confirms binding of ER*α* to sites near the *Dhcr24*, *Ngfr*, and *Wnt4* transcripts. All three tested sites have basal ER*α* binding (V) that is increased by E2 or IGF1 activation. \**P* \< 0.05, \*\*\*\**P* \< 0.0001 vs V; \#\#\#\# *P* \< 0.0001 E2 vs IGF1. Black = V, gray = E2, white = IGF1. A pool of three uterine samples was tested per treatment; assay done in triplicate.](en.2017-00349f5){#F5}

Discussion {#s9}
==========

Our study advances the understanding of the mechanisms that underlie IGF1-mediated uterine responses. IGF1 is one of the candidate paracrine growth factors induced by stromal ER*α* that leads to epithelial cell growth. The ability of E2 to increase epithelial cell proliferation in mice with uterine epithelial cell ER*α* deletion supports this paracrine mechanism ([@B3]). Our observations that ICI was unable to inhibit IGF1 responses in WT mice and of robust transcriptional response of the ER*α*-null mouse uterus to IGF1 seemed to indicate ER*α*-independent growth factor activity. To better test the impact of ER*α* specifically within the uterus, we added the study of the uterine specific ER*α* knockout mice. We used the second ER*α*-null model to address defects potentially arising from global ER*α* deletion; however, we did not find differences in the transcriptional responses of these two ER*α*-null models that informed the understanding of the role of ER*α* in the overall response. This indicates that the differences in IGF1 responses of the WT and ER*α*-null context are intrinsic to the uterine cells.

ER*α*-mediated responses to E2 include induction of IGF1, which then signals through its receptor-mediated pathway. We previously demonstrated E2-dependent recruitment of ER*α* to uterine chromatin, both at the *IGF1* TSS ([@B14]) and at an enhancer approximately 50 KB 5′ of the *IGF1* TSS ([@B16]). However, direct treatment with IGF1 leads to growth and transcriptional responses, and in the WT mouse, is not wholly dependent on ER*α* ([Fig. 6](#F6){ref-type="fig"}). The transcripts highlighted in [Fig. 3(a)](#F3){ref-type="fig"} use this ER*α*-independent mechanism. Because these transcripts were differentially expressed regardless of whether ER*α* was present, we hypothesized that IGF1 ER*α* binding would be less likely to occur nearby. Indeed, when we compared active genes nearest to overlapping E2 and IGF1 ER*α* ChIP-seq peaks to these ER*α*-independent differentially expressed genes, 223 of the 262 DE coding genes did not overlap with genes closest to ER*α* binding peaks \[Supplemental Fig. 4(b)\]. Neither E2 nor IGF1 increased ER*α* binding near the *Ppargc1a* or *Adamts5* genes \[Supplemental Fig. 4(c)\], yet either agent repressed transcription. Hence, although the E2-mediated regulation of these transcripts required ER*α*, chromatin binding by other factors might be involved. E2 increases ER*α* binding at the *Fos* TSS and at 5′ and 3′ enhancers \[Supplemental Fig. 4(c)\]. IGF1 also increases ER*α* binding at the *Fos* 3′ enhancer, and part of the 5′ enhancer \[Supplemental Fig. 4(c)\]. However, IGF1 does not increase ER*α* binding at two of the smaller 5′ enhancers or at the main peak of ER*α* near the *Fos* TSS \[highlighted by boxes in Supplemental Fig. 4(c)\]. These E2-induced ER*α* peaks were not within the overlapping E2 and IGF1 ER*α* peaks in [Fig. 4(c)](#F4){ref-type="fig"}. Some, but not all, of the ER*α* peaks near *Fos* are induced by either E2 or IGF1. The ability of E2 to induce ER*α* binding at more sites than IGF1 is likely why E2 is more robust than IGF1 in increasing *Fos*. Other genes, including the transcripts in [Fig. 4(a)](#F4){ref-type="fig"}, are regulated by direct IGF1-initiated activation of ER*α*. Consistent with an E2 ligand--independent ER*α*-dependent mechanism for these transcripts, several of the ER*α*-dependent genes exhibited E2 or IGF1-mediated ER*α* binding in the ChIP-seq datasets \[Supplemental Fig. 4(a)\]. It is interesting to note that, based on the microarray data, 64% of the 654 ER*α*-independent IGF1-regulated transcripts were downregulated, whereas the proportion of 230 ER*α*-dependent transcripts that were downregulated was 44%, suggesting that the repression mechanism is less likely to involve direct ER*α* interaction.

![Model: Role of ER*α* in adult uterine growth and IGF1 crosstalk. Left: ER*α*-independent response to IGF1. E2, through action of ER*α* in uterine stromal cells, induces IGF1, which then binds to IGF1 receptors on epithelial cells. The IGF1 receptor signaling leads to regulation of gene products. Direct treatment with IGF1 induces similar transcriptional responses, and does not require uterine ER*α*. Right: ER*α*-dependent/transcriptional cross talk in uterine cells. Both E2 and IGF1 can induce genes through the ER*α*. IGF1/IGF1R signals through ER*α*. E2 and IGF1 induce similar responses but require the ER*α* gene products are mostly upregulated.](en.2017-00349f6){#F6}

ChIP-seq of uterine ER*α* showed that E2, IGF1 and ICI all increase ER*α* peaks ([Table 1](#T1___1){ref-type="table"}), indicating several details about the mechanisms of these different compounds. First, ER*α*-dependent IGF1-induced responses occur downstream of chromatin binding, and this may explain why ICI did not universally inhibit these responses, as IGF1 activates ER*α* through its AF-1 region, whereas ICI primarily impacts functions on the ligand binding/AF-2 region. Second, although ICI inhibits ER*α* activity both by decreasing ER*α* protein and preventing ER*α*-coactivator interactions, it is clearly also capable of inducing ER*α* chromatin binding. The Chip-seq samples were collected 1 hour after ICI treatment, at which time ER*α* is found in the nucleus, and before ER*α* degradation has occurred ([@B17]). Third, Hoxa9 and Egr1 motifs are significantly enriched in IGF1-induced ER*α* peaks relative to E2-induced peaks \[[Fig. 4(b](#F4){ref-type="fig"})\], suggesting these transcriptional modulators may impact ER*α*-dependent IGF1 response. EGR1 and several members of the homeobox family are detected in the mouse uterus and known to play essential roles in uterine function ([@B18][@B19]). Homeobox motifs are enriched in general in the non-ERE containing ER*α* binding sites in the mouse uterus ([@B16]). Although a mouse uterine EGR1 cistrome has not been reported, data from mouse kidney indicated that EGR1 tended to interact with sites proximal to TSS ([@B20]), unlike ER*α*, which exhibits mostly distal interactions ([@B16]). Additionally, epidermal growth factor (EGF) activation of mitogen-activated protein kinase signaling caused EGR1 binding to EGF target genes in prostate cells ([@B21]). Because EGF and IGF1 can both activate MAP kinases, it is possible that IGF1 can induce EGR1 binding to the IGF1-responsive transcripts in the mouse uterus. ERE motifs were prevalent in E2 and IGF1 overlapping ER*α* peaks \[[Fig. 4(b](#F4){ref-type="fig"})\] indicating that direct interactions drive much of the response.

Overall, our study indicates that direct treatment with IGF1 increased ER*α* recruitment to chromatin, driving regulation of ER*α*-dependent transcripts, consistent with crosstalk of signals from the IGF1 pathway to the ER*α* ([Fig. 6](#F6){ref-type="fig"}). Additionally, IGF1 treatment can directly activate responses independent of ER*α*, consistent with the mechanism of paracrine uterine response and regulation. These observations impact our understanding of E2 and IGF1 signal responses in a whole animal model. Such knowledge has potential applications to reproductive health of humans, livestock, and wildlife.

Abbreviations: *Adamts5*a disintegrin-like and metallopeptidase with thrombospondin type 1 motif, 5ChIPchromatin immunoprecipitationChIP-seqchromatin immunoprecipitation sequencingDEdifferentially expressed*Dhcr24*24-dehydrocholesterol reductaseE2estrogenEGFepidermal growth factorEgr1early growth response 1ER*α*estrogen receptor *α*EREestrogen response element*Fos*FBJ osteosarcoma oncogeneGEOGene Expression OmnibusIGF1insulinlike growth factor 1IGF1Rinsulinlike growth factor 1 receptor*Map2k6*mitogen-activated protein kinase kinase 6*Ngfr*nerve growth factor receptorNIEHSNational Institute of Environmental Health SciencesPCRpolymerase chain reactionPGRprogesterone receptor*Ppargc1α*peroxisome proliferator-activated receptor γ coactivator 1-*α*RRIDresearch resource identifierRT-PCRreal-time polymerase chain reactionTSStranscription start siteWTwild-type.
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###### 

**Antibody Table**

  Peptide/Protein Target   Antigen Sequence (if Known)   Name of Antibody            Manufacturer, Catalog No., and/or Name of Individual Providing the Antibody   Species Raised in; Monoclonal or Polyclonal   Dilution Used   RRID
  ------------------------ ----------------------------- --------------------------- ----------------------------------------------------------------------------- --------------------------------------------- --------------- ------------
  ESR1                                                   ER-1D5                      Biocare Medical, ACA 054C                                                     Mouse; monoclonal                             1:200           AB_2651037
  Ki67                                                   Purified mouse anti-Ki-67   BD Pharminogen, 550609                                                        Mouse; monoclonal                             1:100           AB_393778
